TL;DR
This paper provides a data-driven "map" of the lung organoid research landscape from 2011 to 2024 using bibliometric analysis. It reveals an exponential growth in the field, identifies the U.S. and the Netherlands as the primary research hubs, and highlights a critical shift from basic model construction toward complex clinical applications like COVID-19 drug screening and "lung-on-a-chip" systems.
What Problem Does This Paper Address?
Traditional 2D cell cultures fail to replicate the complex 3D architecture of human lungs, while animal models often don't translate well to human clinical outcomes. Lung organoids—3D tissue-like structures grown from stem cells—offer a promising middle ground.
However, as the field has exploded, it has become difficult for researchers to track global trends, identify key collaborators, or objectively determine which research "hotspots" are most deserving of attention. Most existing reviews are subjective; this paper uses quantitative bibliometrics to provide an objective overview of the field’s evolution, current state, and remaining hurdles to clinical adoption.
Methods
The authors performed a bibliometric analysis using data from the Web of Science Core Collection (WoSCC). They filtered 4,253 initial results down to 929 high-quality articles and reviews published between 2011 and 2024.
To visualize and analyze this data, they employed:
- R (Bibliometrix package): For quantitative analysis of publication trends and "dumbbell charts" to track hotspot evolution.
- VOSviewer: For co-authorship and keyword co-occurrence mapping.
- SCImago Graphica: For geographic and institutional collaboration visualization.
- Bradford’s and Price’s Laws: Standard bibliometric statistical models used to identify "core" journals and "core" authors, respectively.
Datasets
The primary dataset was extracted from the Web of Science Core Collection (WoSCC). The authors specifically focused on English-language articles and reviews, excluding unrelated fields like environmental science or agriculture to ensure a clean dataset focused strictly on biomedical lung organoid research.
Key Insights and Ideas
- Exponential Growth: The field is in a "rapid rise" phase. Publications grew from a single paper in 2011 to nearly 200 annually by 2023, maintaining a 49.1% annual growth rate.
- The "Clevers" Influence: Hans Clevers (Netherlands) emerged as the most influential author, pioneering the stem cell technologies that allow for functional lung organoid creation.
- Geographic Dominance vs. Impact: While the USA produces the highest volume of papers and citations, the Netherlands has the highest average citations per article (72.80), indicating a very high impact-per-paper ratio.
- The COVID-19 Catalyst: The pandemic significantly accelerated the field. Organoids became essential for studying SARS-CoV-2 entry, replication, and antiviral testing (e.g., Remdesivir) in a human-relevant context.
- Four Disease Pillars: Research has naturally clustered into four main clinical areas:
- IPF (Idiopathic Pulmonary Fibrosis): Focusing on alveolar regeneration.
- Lung Cancer: Using patient-derived organoids (PDOs) for personalized drug screening.
- Cystic Fibrosis (CF): Using CRISPR/Cas9 to correct genetic mutations.
- COVID-19: Modeling viral-host interactions.
Key Results
- Top Journal: Nature holds the highest citation count (2,675), while Nature Communications published the most articles (24).
- Top Institution: University Medical Center Utrecht (Netherlands) leads with 2,083 citations.
- Keyword Evolution: Early research focused on "stem cells" and "Wnt signaling" (the "how-to" of building models). Recent hotspots have shifted to "microphysiological systems" (organ-on-a-chip) and "disease modeling" (the "how-to-use" phase).
- Collaboration Gaps: Despite the growth, the co-authorship network is fragmented into 14 distinct clusters, suggesting that the field lacks a unified, global collaboration model.
Limitations and Future Work
The authors identify several "pressing challenges" that currently block the path to widespread clinical use:
- Standardization: There is a lack of consensus on culture conditions and data analysis, leading to inconsistencies in organoid morphology and function.
- Model Immaturity: Current organoids often represent "immature" lung tissue, making it difficult to mimic adult diseases perfectly. Future work needs to integrate biomechanical scaffolds and immune cell co-cultures.
- Ethics and Safety: Issues surrounding the source of stem cells, gene editing (CRISPR) risks, and the long-term safety of organoid transplantation remain unresolved.
- Data Source: The study only used the WoSCC database. While high-quality, it may have missed relevant papers indexed in PubMed or Scopus.
The paper concludes that the next frontier lies in microphysiological systems—integrating organoids with microfluidics to better simulate the "breathing" lung environment.
Summary updated